The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
Matti S. Aapro
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics
Research Funding - Helsinn Therapeutics
Other Remuneration - Helsinn Therapeutics
Giorgia Rossi
Employment or Leadership Position - Helsinn Therapeutics
Giada Rizzi
Employment or Leadership Position - Helsinn Therapeutics
Marco Palmas
Employment or Leadership Position - Helsinn Therapeutics
Steven Grunberg
Consultant or Advisory Role - A.P. Pharma; Helsinn Therapeutics; Merck Sharp & Dohme; RedHill Biopharma; Tesaro
Stock Ownership - Merck
Honoraria - Eisai; Merck